Introduction
Alzheimer's disease (AD) is preceded by a very long presymptomatic or prodromal phase. Biomarkers able to detect the in vivo changes of the amyloid b (Ab) peptides, and tau proteins improve diagnosis and detection of at-ADrisk subjects. Among these biomarkers, cerebrospinal fluid (CSF) Ab 42 , tau, phosphorylated tau (p-Tau), and cortical amyloid-positron emission tomography (PET) scans have been included in the International Guidelines for AD diagnosis in clinical research settings [1] . CSF Ab 42 is reduced at least 15 years before symptoms' onset [2] , and the relevance of CSF amyloid has been confirmed for positive [3] , differential [4] , and early phases (mild cognitive impairment [MCI] and prodromal AD) [5] . A strong correlation is observed between CSF Ab 42 and cortical amyloid-PET in AD. Lumbar puncture remains an invasive technique, and amyloid-PET is still expensive and not a screening tool. This highlighted the need of less invasive and expensive biomarkers that could predict central amyloid status. The most promising biomarker seems to be the plasma Ab 42 , although previous studies have controversial results. Elderly nondemented participants with a higher plasma Ab 42 level and a lower plasma Ab 42 /Ab 40 ratio at baseline have an increased risk of dementia [6] . A decrease of plasma Ab 42 level is associated with the progression from controls and MCI to AD [7] . Others studies yield conflicting results regarding the predictive value of plasma Ab 42 for AD diagnosis and for cognitive decline in at-AD-risk population [4, 6, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] ; meanwhile, the combination of plasma Ab 42 levels and others biomarkers might improve the predictive value [14, 20] . Recently, innovative technique allows the quantification of amyloid in plasma with complex proteomics techniques, so far hardly implementable in routine [21] . Although discrepancies between studies can be explained by many factors, the missing link remains the understanding of the relationship between peripheral and central biomarkers at early stage of the disease.
Therefore, the aim of this study was (1) to assess the plasma levels of amyloid Ab and Ab in a large clinically based cohort of amnestic MCI (aMCI), nonamnestic MCI (naMCI), and AD patients and (2) to investigate the relationships between plasma Ab 1-42 , Ab , CSF, and brain imaging biomarkers in a large prospective cohort taking into account potential confounding factors.
Methods

Study population
BALTAZAR (Biomarker of AmyLo€ ıd pepTide and AlZheimer's diseAse Risk) is a multicenter (23 memory centers) prospective cohort study (ClinicalTrials.gov Identifier #NCT01315639) including participants with MCI or AD at baseline from September 2010 to April 2015 and with an ongoing 3-year follow-up. All participants were Caucasian, community-dwellers and had caregivers. To follow more recent diagnostic criteria [24] , we reclassified MCI participants in MCI core-clinical, MCI low-likelihood, MCI intermediate-likelihood, and MCI high-likelihood groups, based on the positivity of amyloid and neuronal injury biomarkers such as CSF Ab 42 for amyloid biomarkers and CSF tau or the presence of an MRI hippocampal atrophy for neuronal injury.
All participants or their legal guardians gave written informed consent. The study was approved by the Paris Ethics Committee (CPP Ile de France IV Saint Louis Hospital).
Plasma and CSF sampling and analysis
Blood and CSF samples were collected on the same day and time of the day. People involved in biological analysis were blinded to other assessments. A standard protocol was established beforehand and used throughout the study. C. Biomarker measurements were performed in a single centralized laboratory (UMRS1172 former INSERM U837; Lille, France). Plasma Ab peptide assay was performed using the INNO-BIA kit (Fujirebio Europe NV, formerly Innogenetics NV, Belgium), based on a multiplex xMAP technique with a LABScan-200 system (Luminex BV, The Netherlands). Ab peptide levels from each blood draw were measured in duplicate using the same aliquot.
Lumbar CSF samples were collected according to a standardized protocol [25, 26] . CSF samples (.4 mL) were centrifuged (1000 g, 14 C, 10 minutes) less than 4 hours after collection using the same 10 mL polypropylene tube (ref62.610.201; Sarstedt, Germany) and aliquoted into polypropylene protein low-binding tubes (LoBind microtube-ref 022431064; Eppendorf) and stored at 280 C
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. CSF Ab 42 , total-tau, and p-Tau 181P levels were measured in duplicate using the same aliquot in a single centralized laboratory (IRMB, Montpellier, France) using commercially available Innotest sandwich ELISA INNOT-EST hTAU Ag, INNOTEST b Amyloid , and INNOT-EST Phospho-tau (181P) according to the manufacturer's procedures (Fujirebio Europe N.V., Belgium). Owing to procedure's constraints, concentrations of total-tau above the detection limit (.1200 pg/mL) were not recalculated after dilution.
MRI examination
The MRI protocol included a three-dimensional volumetric T1-weighted, an axial FLAIR T2W, an axial EG T2W, and an axial T2W FSE Q12 with slices angled parallel to axis through the genu and splenium of the corpus callosum and taken from foramen magnum to vertex. The protocol also included an axial blood-oxygen-level dependent echo planar EPI Q13 (10 minutes resting state), an axial diffusion tensor imaging (b-factor 5 1000 s/mm 2 ; 32 directions). After MRI
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, the scans were sent for quality validation and postprocessing. MRI analysis was centralized and analyzed by the Centre d'acquisition et de traitement d'images [27] . Right and left hippocampal volumes were obtained for each participant using automatic segmentation of the hippocampus [28] .
Potential confounding and moderating variables
The standardized interview included questions on demographic and socioeconomic characteristics, health status, and medication use. Cerebrovascular and cardiovascular diseases were defined as self-reported history of stroke and cardiovascular events; diabetes as a self-reported diagnosis of diabetes or fasting blood glucose .7.0 mmol/L or use of glucose-modifying medication; dyslipidemia, smoking habits defined as never, former, or current; or hypertension defined as a measured systolic blood pressure 140 mm 244  245  246  247  248  249  250  251  252  253  254  255  256  257  258  259  260  261  262  263  264  265  266  267  268  269  270  271  272  273  274  275  276  277  278  279  280  281  282  283  284  285  286  287  288  289  290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310   311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335  336  337  338  339  340  341  342  343  344  345  346  347  348  349  350  351  352  353  354  355  356  357  358  359  360  361  362  363  364  365  366  367  368  369  370  371  372  373  374  375  376 Hg or diastolic 90 mm Hg or current use of antihypertensive treatment. Each participant had a physical examination performed by a physician with calculation of the body mass index (BMI) and Mini Nutritional Assessment. Functional disability was assessed using activities of daily living (normal score 6/6) and instrumental activities of daily living (normal score 14/14) scales. Depressive symptoms were evaluated with the GDS. Apolipoprotein E (APOE
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) was genotyped in a single centralized laboratory (Centre de Biologie-Pathologie, Lille University Hospital, France) using a classical PCR Q16 digestion method.
Statistical analysis
General characteristics were analyzed in the whole sample and according to AD, aMCI, or naMCI diagnosis. Categorical variables are presented as percentage and number of subjects [% (N)], continuous variables as mean and standard deviation [M (SD)], and comparisons were made with c 2 or analysis of variance. Means levels of plasma and CSF biomarkers were calculated in the three groups and compared first with generalized linear regression with and without adjusted for age, sex, education level, and number of APOE ε4 allele with biomarkers as dependent variables and diagnosis treated nominally and ordinally (coded in the following order AD, aMCI, and naMCI) to assess a linear relationship. The models were further adjusted for systolic blood pressure, BMI, diabetes, history of stroke or transient ischemic attack, and dyslipidemia. Because all biomarkers had a skewed distribution, they were log-transformed for statistical testing; but for the sake of clarity, non-log-transformed biomarker means and standard deviations are presented. We performed a sensitivity analysis excluding AD patients aged 70 years (n 5 69, 13.7%) to exclude early-onset AD that could carry presenile PS1 and PS2 mutations that may be associated with different forms of b amyloid. Relationships between CSF Q17 and plasma biomarkers were assessed in the whole sample and among AD, aMCI, and naMCI patients separately with Pearson correlation coefficients and with general linear regression models with plasma biomarkers as dependent variables and CSF biomarkers as independent variables adjusted for variables associated with plasma biomarkers (age and presence of APOE ε4 allele) and sex ( Q18 Table 3 ). Because of the small number of naMCI patients, we also analyzed correlation in the MCI group as a whole. Results of correlations of the plasma Ab 1-42 and the CSF biomarkers are presented in scatter plots with regression and 95% confidence interval lines. Pearson correlation coefficients between plasma biomarkers and age, MMSE, and hippocampal volume were calculated. The same analyses were performed after reclassification of participants as per Albert' criteria [24] . Statistical analysis was performed using the R statistical software. In all analyses, the two-sided a-level of 0.05 was used for significance testing.
Results
Demographical, clinical, and MRI characteristics
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One thousand forty participants were included (501 AD, 417 aMCI, and 122 naMCI). There were more women in the naMCI group (P 5.004). Educational level differed between groups (P , .0001). No between-group difference for age, smoking status, BMI, comorbidities, or GDS was observed. AD and aMCI carried more often APOE ε4 allele (P , .0001) and had a lower MMSE score compared to naMCI participants (P , .0001). The activities of daily living and instrumental activities of daily living scores were lower in AD than in MCI and aMCI participants. Among the MCI Q20 participants, the free and cued selective recall reminding test score was lower in aMCI than naMCI participants. All cognitive assessments were different between both groups except motor planning (Supplementary Table 1 ). Hippocampal volume measured in 837 participants was different between AD, aMCI, and naMCI (P , .0001) and between aMCI and naMCI (P , .0001; Table 1 ; Flow chart, Fig. 1 ).
Plasma and CSF biomarker characteristics
The levels of plasma Ab and Ab were lower in AD than in aMCI, than in the naMCI participants (for Ab [pg/mL]: 36.9 [11.7] were still significant (P 5 .05 and P 5 .02, respectively). When the model was adjusted for age, sex, and cardiovascular comorbidities (history of stroke or transient ischemic attack, systolic blood pressure, BMI, diabetes, and dyslipidemia), the relation was still significant for Ab 1-42 (P 5 .04) but not for Ab 1-40 (P 5 .47). The Ab 1-42 /Ab 1-40 ratio showed an opposite variation without reaching significance. A reduction of 3.7% from naMCI to aMCI and of 7.3% from naMCI to AD was found for plasma Ab . For plasma Ab 1-40 , the percentage of reduction was lower (1.1% from naMCI to aMCI and 3.3% from naMCI to AD) ( Table 2) .
The sensitivity analysis excluding AD patients aged 70 years and younger showed the same significant associations between cognitive status and Ab 1-42 (P 5 .04) and Ab 1-40 (P 5 .02).
From naMCI to aMCI and to AD, CSF Ab 42 levels were progressively lower and CSF tau, p-Tau, and p-Tau/Ab 1-42 ratio levels were progressively higher
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. For CSF Ab , there was a 13.9% reduction from naMCI to aMCI and a 28.1% reduction from naMCI to AD. All the results were obtained after adjustment for age, sex, educational level, and APOE ε4 status.
Correlations between plasma amyloid biomarkers Q22 and the other parameters are shown in Table 3 , Fig. 2 , and Supplementary Table 2 .
Plasma Ab 1-42 correlated with age in AD, all MCI and aMCI (P , .001 for all), and with MMSE in the AD group (P 5 .04). In all MCI, plasma Ab 1-42 was associated with the presence of APOE ε4 allele (P 5 .003) and CSF Ab 42 , Tau, p-Tau and p-Tau/Ab 42 ratio (P 5 .02, P 5 .01, P 5 .02 and P 5 .002 respectively) ( Fig. 2 and Supplementary Table 2 ). In aMCI groups, plasma Ab 1-42 was associated with APOE ε4 allele (P 5 .03) and with Tau, p-Tau and p-Tau/Ab 42 ratio (P 5 .02, P 5 .03, P 5 .004, respectively; Fig. 2 Table 2 ).
Significant relationships between CSF and plasma biomarkers remained significant when the models were adjusted for age, sex, and presence of APOE ε4 allele (see Supplementary Table 2) .
No correlation between hippocampal volume and plasma Ab was found, however a correlation was observed between the plasma Ab , P 5 .14 respectively). However, the differences of Ab 1-42 between MCI low-likelihood and MCI high-likelihood was significant (P 5 .03).
Discussion
In our study, plasma Ab 1-42 and Ab 1-40 levels were lower in AD than in aMCI than in naMCI participants. Interestingly, plasma Ab 1-42 correlated with the three CSF 512  513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540  541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578   579  580  581  582  583  584  585  586  587  588  589  590  591  592  593 biomarkers in all MCI but only with CSF Ab 42 in AD. A correlation was also found between plasma Ab 1-42 and MMSE in AD. In aMCI participants, plasma Ab 1-42 correlated with CSF tau and p-Tau. Taking into account preanalytical and analytical potential confounding factors, our findings suggested the relevance of plasma amyloid biomarkers in the Alzheimer's process. We confirmed also previous results [17, 29] . Our data are in accordance with the potential different kinetic of plasma Ab levels in AD, in MCI, and in controls, with higher baseline levels in naMCI than aMCI and a decrease in MCI at-risk for AD [30] . . Abbreviations: AD, Alzheimer's disease; aMCI, amnestic mild cognitive impairment; CSF, cerebrospinal fluid; MCI, mild cognitive impairment; naMCI, nonamnestic mild cognitive impairment. Abbreviations: AD, Alzheimer's disease; CSF, cerebrospinal fluid; M (SD), mean (standard deviation); MCI, mild cognitive impairment; p-Tau, phosphorylated tau.
*Comparison between the three groups with linear regression adjusted for age, sex, educational level, and the presence of the APOE ε4 allele.
Plasma Ab and Ab 1-40 levels were
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progressively lower from naMCI to aMCI and to AD participants. This result is in accordance with recent study that also observed both plasma Ab and Ab 1-40 decreases in AD [29] but not in others [32] [33] [34] . The decrease of plasma amyloid level during the Alzheimer's process could be explained by Ab clearance's decrease from the brain (CSF) to the peripheral fluid (blood) because of alteration of blood-brain barrier permeability, glymphatic system, or vascular or microglial activation troubles [35, 36] . Interestingly, the proportion of Ab reduction between the clinical groups was similar in the two fluids (3.7% and 7.3% in plasma and 14% and 28% in CSF for aMCI vs. naMCI and AD vs. naMCI, respectively). This suggests that plasma Ab 42 variations reflect CSF Ab 42 variations. It remains difficult to argue for or against the peripheral sink theory hypothesizing that the reduction of Ab peptides in the blood is a mechanism to diminish Ab levels and plaque load in the brain. Our results also fit the second part of the Song et al. model [7] in which plasma Ab 42 decreases during the course of the disease. For the first part, Song et al. hypothesize that Q25 plasma Ab 42 levels are higher in MCI subjects when compared to controls. In the present study, no control group was included but the longitudinal follow-up of the BALTAZAR study will enable the comparison of repeated measures of plasma Ab over time and the analysis of their changes according to Alzheimer's continuum. Plasma Ab 1-42 correlated with CSF Ab 42 biomarkers in MCI and AD patients. This correlation has been previously described with amyloid brain lesions in postmortem [37, 38] and PET-PIB Q26 imaging studies. In the BioFINDER study including 719 elderly subjects with subjective cognitive decline, MCI, AD, and healthy cognition, the Ab 42 level is lower in AD compared to control, subjective cognitive decline, and MCI groups and that low plasma Ab 42 and Ab 42 /Ab 40 ratio are associated with brain amyloid deposits measured by amyloid-PET [29] .
Interestingly, we found that plasma Ab 1-42 negatively correlated with CSF tau and p-Tau only in MCI participants. Plasma Ab 42 levels may be correlated with some specific release of tau forms in the early stages of AD process. CSF tau forms are numerous (splice variants, phosphorylated/glycosylated forms, truncated and membrane associated forms, etc.) [39, 40] . The relationship between plasma Ab 1-42 and tau could be of two types: either (1) direct, Ab 42 has been shown to induce tau phosphorylation [41] or (2) mechanisms influencing amyloid and tau metabolism, that is, lipid and glucose metabolism or APOE [42] . In this way, recent findings show that Ab 42 influences neuronal death that increases release of tau aggregation competent forms [43] . Another hypothesis could be that the dynamic of plasma Ab 42 , CSF p-Tau, and tau levels differs at MCI and AD stages. Level of tau and p-Tau increases during the MCI stage of the disease and reaches a plateau at the demented stage [2] . At the latest stage, the remaining neurons are probably not numerous enough to maintain the increase of CSF tau and p-Tau, and the Ab in the plasma and tau processes are thus dissociated. According to amyloid cascade, a certain amount of soluble Ab 42 could be needed in periphery to affect brain tau metabolism, and the alteration of the blood-brain barrier permeability within the process could influence the toxicity of peripheral amyloid products. Inversely tau aggregation
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seems influenced Ab metabolism and elimination from brain [44] .
Despite correlations between plasma Ab 42 and tau markers, we only found a trend between high level of plasma Ab 40 and a reduction of the hippocampal volume, which is consistent with the findings of the 3C study in which higher plasma Ab 40 is correlated to a higher atrophy score in dementia-free older adults [45] but not with the results of the Sydney Memory and Ageing Study [46] .
The strength of our study lies in the large number of well-characterized participants with harmonized and standardized cognitive tests. We optimized the data through reclassified participants based on CSF or MRI biomarkers to determine amyloid and neuronal injury process. All the biochemical analyses were centralized in a single laboratory, eliminating intercenter variability. To limit confounding effects, the same preanalytical protocol was followed throughout the study, with shipment to all centers of the same collection tubes. The same lot was used for measurement of plasma amyloid levels at inclusion. We used the commercially available Luminex technology that has good analytical performances and clinical sensitivity and is already used in routine [47] . In addition, the brain MRI was analyzed in one dedicated expert center.
The present study has some limitations. No amyloid-PET imaging or neuropathological confirmation was available. The analysis is cross-sectional, as the clinical, neuropsychological, and imaging follow-up is still ongoing. We did not adjust the analysis for MCI duration although it may have affected both plasma and CSF biomarkers levels because duration of MCI disease is very difficult to assess and were thus not recorded. Inclusion of healthy controls would have provided a better evaluation of plasma Ab as a marker of MCI; however, we did not include healthy controls because it is ethically difficult to propose a lumbar puncture to subjects without cognitive complaint. The prospective design of the BAL-TAZAR study will enable the analysis of predictive value of plasma Ab for conversion from MCI to AD and severe worsening of AD.
To conclude, our findings open new insights to better understand the link between peripheral and central biomarkers within the Alzheimer's process at an early stage. Plasma Ab was associated with cognitive status and CSF biomarkers. Plasma Ab and Ab 1-40 levels were lower in AD than in aMCI than in naMCI participants. This needs to be further investigated in a longitudinal follow-up to assess the potential prognosis relevance of plasma amyloid biomarkers. Regarding the correlation between plasma Ab 42 and CSF tau biomarkers in MCI, further studies including PET-tau biomarkers and new innovative techniques to detect specific tau forms will be interesting. 1182  1183  1184  1185  1186  1187  1188  1189  1190  1191  1192  1193  1194  1195  1196  1197  1198  1199  1200  1201  1202  1203  1204  1205  1206  1207  1208  1209  1210  1211  1212  1213  1214  1215  1216  1217  1218  1219  1220  1221  1222  1223  1224  1225  1226  1227  1228  1229  1230  1231  1232  1233  1234  1235  1236  1237  1238  1239  1240  1241  1242  1243  1244  1245  1246  1247  1248 
